KR970702915A - 종양 세포의 치료 감응성 향상 방법(Enhancing The Sensitivity of Tumor Cells to Therapies) - Google Patents
종양 세포의 치료 감응성 향상 방법(Enhancing The Sensitivity of Tumor Cells to Therapies)Info
- Publication number
- KR970702915A KR970702915A KR1019960706063A KR19960706063A KR970702915A KR 970702915 A KR970702915 A KR 970702915A KR 1019960706063 A KR1019960706063 A KR 1019960706063A KR 19960706063 A KR19960706063 A KR 19960706063A KR 970702915 A KR970702915 A KR 970702915A
- Authority
- KR
- South Korea
- Prior art keywords
- cells
- therapeutic
- gene
- tumor cells
- cdna
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Marine Sciences & Fisheries (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
본 발명은 돌연변이체 치료 증감화 유전자 활성을 갖는 종양 세포중에 야생형 치료 증감화 유전자 활성을 도입시키고 상기 종양 세포를 화학 요법, 방사선 요법, 면역요법을 포함한 생물학적 요법, 한냉요법 및 과온증요법과 같은 암치료 법으로 처리함으로써 암치료 효과를 향상시키는 방법에 관한 것이다.
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 T98G 신경교아세포총 세포(폐쇄된 환) 및 이중에서 발현되는 야생형 p53을 갖는 동일한 세포인 T98Gp53 세포(개방환)의 시스플라틴 감응성을 나타낸다,
제2도는 T98G 신경교아세포종 세포(상부 곡선) 및 T98Gp53 세포 (하부 곡선)의 방사선 감응성을 나타낸다.
Claims (22)
- 야생형 치료 증감화 유전자 활성이 활성의 상실을 특징으로 하는 종양 세포에 야생형 치료 증감화 유전자 활성을 전달하는 단계; 및 상기 종양 세포를 암치료하는 단계를 포함하는, 암치료 효과 향상 방법.
- 제1항에 있어서, 치료 증감화 유전자의 일부 또는 상기 치료증감화 단백질의 일부를 종양 세포에 도입시키는 방법.
- 제1항에 있어서, 치료 증감화 유전자의 일부 또는 상기 치료 증감화 유전자 활성을 암호화하는 cDNA의 일부를 종양 세포에 도입시키는 방법.
- 제1항에 있어서, 암치료가 방사선 요법인 방법.
- 제1항에 있어서, 암치료가 화학 요법인 방법.
- 제1항에 있어서, 암치료가 생물학적 요법인 방법.
- 제1항에 있어서, 암치료가 한냉요법인 방법.
- 제1항에 있어서, 암치료가 과온증 요법인 방법.
- 제1항에 있어서, 상기 종양 세포가 암종 세포, 육종 세포, 중추신경계 종양 세포, 흑색종 종양 세포, 백혈병 세포, 임파종 종양 세포, 조혈성 종양 세포, 난소 암종 세포, 골형성원성 육종 세포, 폐 암종 세포, 결장직장 암종 세포, 간세포 암종 세포, 망막아종 세포, 전립선암 세포, 유방암 세포, 방광암 세포, 신장암 세포, 췌장암 세포, 위암 세포, 식도암 세포, 직장암 세포, 담낭암 세포, 비뇨생식기암 세포, 및 머리 및 목암 세포로 이루어진 군으로부터 선택되는 것인 방법.
- 제3항에 있어서, 치료 증감화 유전자의 일부 또는 cDNA의 일부가 벡터중에 존재하는 것인 방법.
- 제10항에 있어서, 상기 벡터가 아데노바이러스 벡터, 레트로바이러스 벡터, 아데노-관련 바이러스 벡터, 헤르페스 바이러스 벡터, 종두 바이러스 벡터 및 유두종 바이러스 벡터로 이루어진 군으로부터 선택되는 것인 방법.
- 제3항에 있어서, 치료 증감화 유전자의 일부 또는 cDNA 의 일부를 바이러스 캡시드 또는 입자에 커플링 시키는 방법.
- 제12항에 있어서, 치료 증감화 유전자의 일부 또는 cDNA의 일부를 폴리리신 가교를 통하여 상기 캡시드 또는 입자에 커플링시키는 방법.
- 제3항에 있어서, 치료 증감화 유전자의 일부 또는 cDNA의 일부를 리포좀중에 캡슐화시키는 방법.
- 제3항에 있어서, 치료 증감화 유전자의 일부 또는 cDNA의 일부를 리간드에 접화시키는 방법.
- 제15항에 있어서, 상기 리간드가 이사알로당단백질인 방법.
- 제3항에 있어서, 치료 증감화 유전자 또는 cDNA의 일부를 직접 주사 또는 에어로졸화 제제에 의해 종양세포로 도입시키는 방법.
- 제3항에 있어서, 치료 증감화 유전자의 일부 또는 cDNA의 일부를 동맥내 주입에 의해 종양 세포로 도입시키는 방법.
- 제3항에 있어서, 치료 증감화 유전자의 일부 또는 cDNA의 일부를 동공내 주입에 의해 종양 세포로 도입시키는 방법.
- 제3항에 있어서, 치료증감화 유전자의 일부 또는 cDNA의 일부를 정맥내 주입에 의해 종양 세포로 도입시키는 방법.
- 제1항에 있어서, 치료 증감화 유전자 활성이 fas 치료 증감화 활성인 방법.
- 제1항에 있어서, 치료 증감화 유전자의 활성이 p53 치료 증감화 활성인 방법.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US23622194A | 1994-04-29 | 1994-04-29 | |
US24881494A | 1994-05-24 | 1994-05-24 | |
US33546194A | 1994-11-07 | 1994-11-07 | |
US08/248,814 | 1994-11-07 | ||
US08/236,221 | 1994-11-07 | ||
US08/335,461 | 1994-11-07 | ||
PCT/US1995/005272 WO1995030002A2 (en) | 1994-04-29 | 1995-04-28 | Enhancing the sensitivity of tumor cells to therapies |
Publications (1)
Publication Number | Publication Date |
---|---|
KR970702915A true KR970702915A (ko) | 1997-06-10 |
Family
ID=27398822
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019960706063A KR970702915A (ko) | 1994-04-29 | 1995-04-28 | 종양 세포의 치료 감응성 향상 방법(Enhancing The Sensitivity of Tumor Cells to Therapies) |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP0758382A1 (ko) |
JP (2) | JPH09512554A (ko) |
KR (1) | KR970702915A (ko) |
AU (1) | AU697088B2 (ko) |
CA (1) | CA2189032A1 (ko) |
WO (1) | WO1995030002A2 (ko) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6410010B1 (en) | 1992-10-13 | 2002-06-25 | Board Of Regents, The University Of Texas System | Recombinant P53 adenovirus compositions |
US5747469A (en) | 1991-03-06 | 1998-05-05 | Board Of Regents, The University Of Texas System | Methods and compositions comprising DNA damaging agents and p53 |
WO1992015680A1 (en) | 1991-03-06 | 1992-09-17 | Board Of Regents, The University Of Texas System | Methods and compositions for the selective inhibition of gene expression |
CZ15498A3 (cs) | 1995-07-17 | 1998-07-15 | Board Of Regents, The University Of Texas System | Konstrukce pro expresi pl6 a její aplikace při léčení rakoviny |
US7163925B1 (en) | 1995-07-17 | 2007-01-16 | Board Of Regents, The University Of Texas System | p16 expression constructs and their application in cancer therapy |
KR20080084528A (ko) * | 2007-03-15 | 2008-09-19 | 제네렉스 바이오테라퓨틱스 인크. | 종양살상형 백시니아 바이러스 암 치료 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0510691B1 (en) * | 1991-04-26 | 2004-11-03 | Osaka Bioscience Institute | DNA coding for human cell surface antigen |
JPH07501942A (ja) * | 1991-11-29 | 1995-03-02 | カイロン コーポレイション | 抗ガン免疫療法用ベクター構成体 |
EP0672159B1 (en) * | 1992-04-24 | 2005-12-28 | Sri International | Homologous sequence targeting in eukaryotic cells |
WO1994006910A1 (en) * | 1992-09-18 | 1994-03-31 | Canji, Inc. | Gene therapy by retroviral vector with tumor suppressive gene |
-
1995
- 1995-04-28 EP EP95918867A patent/EP0758382A1/en not_active Ceased
- 1995-04-28 WO PCT/US1995/005272 patent/WO1995030002A2/en not_active Application Discontinuation
- 1995-04-28 KR KR1019960706063A patent/KR970702915A/ko not_active Application Discontinuation
- 1995-04-28 CA CA002189032A patent/CA2189032A1/en not_active Abandoned
- 1995-04-28 AU AU24628/95A patent/AU697088B2/en not_active Ceased
- 1995-04-28 JP JP7528398A patent/JPH09512554A/ja active Pending
-
2007
- 2007-01-17 JP JP2007007784A patent/JP2007099780A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
EP0758382A1 (en) | 1997-02-19 |
AU697088B2 (en) | 1998-09-24 |
CA2189032A1 (en) | 1995-11-09 |
WO1995030002A3 (en) | 1995-11-30 |
WO1995030002A2 (en) | 1995-11-09 |
AU2462895A (en) | 1995-11-29 |
JPH09512554A (ja) | 1997-12-16 |
JP2007099780A (ja) | 2007-04-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Wang et al. | Correlation between clinicopathology and expression of heat shock protein 70 and glucose-regulated protein 94 in human colonic adenocarcinoma | |
DE69434069D1 (de) | Gentherapie für solide tumoren, papillome und warzen | |
RU96112150A (ru) | Рекомбинантный аденовирусный вектор и способы его применения | |
DK0721510T3 (da) | Anti-cancer-genterapi ved modulering af immunresponsen og/eller den inflammatoriske respons | |
KR970702915A (ko) | 종양 세포의 치료 감응성 향상 방법(Enhancing The Sensitivity of Tumor Cells to Therapies) | |
WO1998035028A3 (en) | An oncolytic/immunogenic complementary-adenoviral vector system | |
Gnant et al. | Regional versus systemic delivery of recombinant vaccinia virus as suicide gene therapy for murine liver metastases | |
US20050031591A1 (en) | Tumor-specific promotor and use thereof | |
Spurbeck et al. | Retroviral vector-producer cell-mediated in vivo gene transfer of TIMP-3 restricts angiogenesis and neuroblastoma growth in mice | |
Weyerbrock et al. | Gene transfer technologies for malignant gliomas | |
Katoh et al. | Heat shock protein expression in human tumours grown in severe combined immunodeficient mice | |
Wilczyńska et al. | Combined delivery of an antiangiogenic protein (angiostatin) and an immunomodulatory gene (interleukin-12) in the treatment of murine cancer. | |
Kanai et al. | Enhanced therapeutic efficacy of oncolytic herpes vector G207 against human non‐small cell lung cancer—expression of an RNA‐binding protein, Musashi1, as a marker for the tailored gene therapy | |
HK1118861A1 (en) | Genes differentially expressed in breast cancer | |
Delamette et al. | In vitro study of IgM polymerization | |
Tateno et al. | Expression of plasminogen‐related gene B varies among normal tissues and increases in cancer tissues | |
Toren et al. | Curable and noncurable malignancies: lessons from paediatric cancer | |
Eshel et al. | Microenvironmental factors regulate Ly-6 A/E expression on Py V-transformed BALB/c 3T3 cells | |
Thiede et al. | Use of p53 as cancer cell target for gene therapy | |
Hecht et al. | A Phase I, multicenter, open-label trial to evaluate the safety of talimogene laherparepvec (T-VEC) injected into liver tumors | |
Li et al. | Polyethylenimine (PEI)-Mediated E1A Increases the Sensitivity of Hepatocellular Carcinoma Cells to Chemotherapy | |
Hung et al. | Hepatoid Adenocarcinoma of the Stomach with Liver Metastasis: Report of a Case | |
McKay | Engineered antibodies to fight melanoma: Recombinant anti-human melanoma antibodies are versatile molecules Neri, D. et al.(1996) J. Invest. Dermatol. 107, 164–170 | |
Nolan et al. | IL-12 anticancer gene therapy: magic bullets from a golden gun: Gene gun-mediated skin transfection with the interleukin 12 gene results in regression of established primary and metastatic murine tumors Rakhmilevich, AL et al.(1996) Proc. Natl. Acad. Sci. USA 93, 6291–6296 | |
Kim et al. | 441. Conditional Replication Competent Adenovirus Ad-mTERT-[Delta] 19 Driven by Human Telomerase Promoter Replicates and Elicits Cytopathic Effect Specifically in Cancer Cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E601 | Decision to refuse application |